a2z-Abdo-Triage
A2z Radiology Ai, Inc. · Decision date Sep 16, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 16, 2026 for a2z-Abdo-Triage, a traditional 510(k) submitted by A2z Radiology Ai, Inc. of Boston under K260906. The device is radiological computer-aided triage and notification software (21 CFR 892.2080, Class II, product codes QAS and QFM) that analyzes abdominopelvic CT images in adults aged 22 and older and flags suspected cases among ten listed findings. The summary names a2z-Unified-Triage (K252366) as predicate and states no reference devices were used. SESE is a clearance, not a PMA approval.
The summary describes cloud-based and on-premises deployment and a Predetermined Change Control Plan, which the database lists as authorized. Standalone performance figures appear for some findings at biased and balanced operating points; the source does not give a full performance table, and no independent clinical or comparative claims are supported here.
The database lists a March 19, 2026 receipt date, while the clearance letter states the application was dated August 13, 2026 and received August 14, 2026; the discrepancy is unresolved in the provided material.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 16, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260906
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- A2z Radiology Ai, Inc.
- Product code
- QAS
- Decision code
- SESE
- Decision date
- Sep 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Radiological Computer-Assisted Triage And Notification Software.
- Applicant
- A2z Radiology Ai, Inc.
- Product code
- QAS
- FDA device class
- 2
FDA decision timeline
K260906 received
Application receipt date recorded by FDA.
K260906 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QAS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Ever Fortune.Ai, Co., Ltd. | 510(k) clearance | Oct 30, 2026 | FDA | |
Rapid ICH (v4.0)K262301 | Ischemaview, Inc. | 510(k) clearance | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
A2z Radiology Ai, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Boston, MA
Sources and methodology
- Original FDA record: K260906
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
